FibroGen, Inc (FGEN) financial statements (2022 and earlier)
Company profile
| Business Address |
409 ILLINOIS STREET SAN FRANCISCO, CA 94158 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 405 | 486 | 507 | 544 | 688 | |||
| Cash and cash equivalents | 171 | 275 | 353 | 434 | 532 | |||
| Short-term investments | 234 | 212 | 154 | 111 | 155 | |||
| Receivables | 17 | 36 | 24 | 41 | 26 | |||
| Inventory, net of allowances, customer advances and progress billings | 31 | 29 | 25 | 21 | 12 | |||
| Inventory | 31 | 29 | 25 | 21 | 12 | |||
| Prepaid expense | 7 | 7 | 7 | 10 | 6 | |||
| Other current assets | 5 | 7 | 1 | 3 | 6 | |||
| Other undisclosed current assets | 8 | 8 | 4 | |||||
| Total current assets: | 474 | 573 | 564 | 622 | 737 | |||
| Noncurrent Assets | ||||||||
| Finance lease, right-of-use asset | 1 | 1 | 1 | 27 | 32 | |||
| Operating lease, right-of-use asset | 91 | 94 | 97 | |||||
| Property, plant and equipment | 28 | 29 | 31 | 31 | 36 | |||
| Long-term investments and receivables | 4 | 3 | 106 | 94 | 0 | |||
| Long-term investments | 4 | 3 | 106 | 94 | 0 | |||
| Restricted cash and investments | 2 | 2 | ||||||
| Other noncurrent assets | 6 | 5 | 5 | 9 | 4 | |||
| Other undisclosed noncurrent assets | 168 | 143 | 5 | 5 | 2 | |||
| Total noncurrent assets: | 300 | 277 | 244 | 166 | 75 | |||
| TOTAL ASSETS: | 774 | 851 | 809 | 787 | 812 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 199 | 175 | 197 | 24 | 8 | |||
| Accounts payable | 26 | 24 | 49 | 24 | 8 | |||
| Accrued liabilities | 173 | 151 | 148 | |||||
| Deferred revenue | 16 | 23 | 25 | 11 | 8 | |||
| Debt | 0 | 0 | 0 | 12 | 12 | |||
| Due to related parties | 0 | 0 | 0 | |||||
| Other undisclosed current liabilities | 11 | 11 | 11 | 120 | 91 | |||
| Total current liabilities: | 225 | 209 | 233 | 167 | 118 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 89 | 91 | 94 | 22 | 29 | |||
| Finance lease, liability | 0 | 0 | 0 | 22 | 29 | |||
| Operating lease, liability | 89 | 91 | 94 | |||||
| Liabilities, other than long-term debt | 213 | 187 | 184 | 190 | 176 | |||
| Deferred revenue | 187 | 162 | 153 | 151 | 138 | |||
| Other liabilities | 26 | 24 | 31 | 38 | 38 | |||
| Other undisclosed noncurrent liabilities | 18 | 18 | 18 | 18 | 19 | |||
| Total noncurrent liabilities: | 319 | 296 | 296 | 230 | 223 | |||
| Total liabilities: | 545 | 505 | 529 | 397 | 341 | |||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 209 | 326 | 261 | 371 | 452 | |||
| Common stock | 1 | 1 | 1 | 1 | 1 | |||
| Additional paid in capital | 1,476 | 1,459 | 1,444 | 1,420 | 1,370 | |||
| Accumulated other comprehensive loss | (4) | (4) | (5) | (5) | (4) | |||
| Accumulated deficit | (1,264) | (1,130) | (1,180) | (1,046) | (915) | |||
| Stockholders' equity attributable to noncontrolling interest | 20 | 19 | 19 | 19 | 19 | |||
| Total stockholders' equity: | 229 | 345 | 280 | 390 | 471 | |||
| TOTAL LIABILITIES AND EQUITY: | 774 | 851 | 809 | 787 | 812 | |||
Income statement (P&L) ($ in millions)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 17 | 156 | 24 | 38 | 44 | ||
| Cost of revenue | (3) | (3) | |||||
| Gross profit: | 13 | 153 | 24 | 38 | 44 | ||
| Operating expenses | (149) | (102) | (158) | (109) | (12) | ||
| Operating income (loss): | (135) | 51 | (134) | (70) | 32 | ||
| Nonoperating income (expense) | 1 | (1) | |||||
| Interest and debt expense | (0) | (0) | (0) | (1) | (1) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (134) | 50 | (134) | (71) | 32 | ||
| Income from equity method investments | 0 | 0 | |||||
| Other undisclosed income (loss) from continuing operations before income taxes | (1) | (0) | (0) | 1 | |||
| Income (loss) from continuing operations before income taxes: | (135) | 50 | (135) | (71) | 33 | ||
| Income tax expense (benefit) | (0) | (0) | 0 | (0) | (0) | ||
| Income (loss) before gain (loss) on sale of properties: | (135) | 50 | (135) | (72) | 33 | ||
| Other undisclosed net income (loss) | 1 | (0) | |||||
| Net income (loss): | (134) | 50 | (135) | (72) | 33 | ||
| Other undisclosed net income attributable to parent | 1 | ||||||
| Net income (loss) available to common stockholders, diluted: | (134) | 50 | (134) | (72) | 33 | ||
Comprehensive Income ($ in millions)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (134) | 50 | (135) | (72) | 33 | ||
| Other comprehensive income (loss) | (0) | 0 | 0 | (0) | (3) | ||
| Comprehensive income (loss): | (134) | 50 | (134) | (72) | 30 | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 1 | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (134) | 50 | (134) | (72) | 30 | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.